£113.87

Horizons in Cancer Research. Volume 73: Volume 73

Oncology

Price data last checked 42 day(s) ago - refreshing...

View at Amazon

We'll watch every seller, every day. One email when your price arrives.

About as cheap as it gets. The only time it was cheaper was 2 months ago.

£114 today · all-time low £112 (May 2026) · usually the usual

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↓ Price chart
when this has been cheap or pricey

↓ Forecast
where the price is heading next

↓ Statistics
all-time high & low, recent range

↑ Price alert
name your number, we'll email you

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

Last 49 days · 49 data points (no recent data)

Historical

Generating forecast…

Price Distribution

Price distribution over 49 days • 4 price levels

Days at Price

Current Price

Price Analysis

Most common price: £113 (33 days, 67.3%)

Price range: £112 - £116

Price levels: 4 different prices over 49 days

Description

In Horizons in Cancer Research. Volume 73, after the identification of some small subgroups with a strong biological-molecular identity, the current evidence regarding the prognostic factors of patients with non-eradicable metastatic disease are examined. The goal is to discuss disease subgroups, which may sometimes provide conditions for decisions that are less compliant with current clinical practice and help define new stratification criteria for patients enrolled in prospective studies. Following this, the authors summarize the current knowledge on breast cancer with an introduction on the traditional markers used in the diagnosis of this disease, followed by an account of the emerging markers. Next, the underlying mechanisms of DNA replication, damage and repair are discussed. Further, RAD51 is proposed as a potential means of managing chemoresistant cancers. Certain drugs and strategies can sensitize chemotherapy via impacting on RAD51, which can be developed as chemotherapy modulators. The authors also discuss multiple myeloma, an incurable malignant tumor of plasma cells of the bone marrow, which is the most common primary neoplasm arising in bone. It causes approximately 1% of cancer-related deaths and is the 2nd most common hematological malignancy in the western world. Later, this collection discusses the prevalence and types of infectious complications that patients with multiple myeloma face, as well as present and emerging therapeutic approaches. The concluding study indicates proteins that have a promising future as new anticancer drugs, in conjunction with the in vitro and/or in vivo effects of these bioactive proteins derived from plants.

Product Specifications

Format: hardcover
ASIN: 1536162736
Category: Books > Subjects > Health, Family & Lifestyle > Medical & Healthcare Practitioners > Internal Medicine > Diseases & Disorders > Oncology
Domain: Amazon UK
Release Date: 15 October 2019
Listed Since: 18 July 2019

Barcode

No barcode data available

Horizons in Cancer Research. Volume 73: Volume 73

About as cheap as it gets. The only time it was cheaper was 2 months ago.

Price History & Forecast

Price Distribution

Price Analysis

Description

Product Specifications

Barcode

Similar Products You Might Like

Multiple Myeloma: 183 (Recent Results in Cancer Research, 183)

Springer - Advances in Biology and Therapy of Multiple Myeloma 2

Multiple Myeloma and Related Disorders (Hodder Arnold Publication)

Multiple Myeloma: Risk Factors, Diagnosis & Treatments (Cancer Etiology, Diagnosis and Treatments)

Treatment of Multiple Myeloma and Related Disorders

Multiple Myeloma: Symptoms, Diagnosis and Treatment (Cancer Etiology, Diagnosis and Treatments Series)

Contemporary Management of Multiple Myeloma

Bone Cancer: Bone Sarcomas and Bone Metastases - From Bench to Bedside

Multiple Myeloma and Other Plasma Cell Neoplasms: 0 (Hematologic Malignancies)

Multiple Myeloma: Methods and Protocols: 113 (Methods in Molecular Medicine, 113)

Multiple Myeloma: 183 (Recent Results in Cancer Research, 183)

Recent Updates on Multiple Myeloma

Springer Multiple Myeloma and Plasma Cell Neoplasms Book

Epidemiology and Biology of Multiple Myeloma

Hematologic Malignancies: Multiple Myeloma and Related Plasma Cell Disorders

Bortezomib in the Treatment of Multiple Myeloma (Milestones in Drug Therapy)

Multiple Myeloma: Methods and Protocols: 1792 (Methods in Molecular Biology, 1792)

Biology and Management of Multiple Myeloma (Current Clinical Oncology)

Multiple Myeloma: Methods and Protocols: 1792 (Methods in Molecular Biology, 1792)

Biology and Management of Multiple Myeloma (Current Clinical Oncology)

Resistance to Targeted Therapies in Multiple Myeloma: 22 (Resistance to Targeted Anti-Cancer Therapeutics, 22)

Resistance to Targeted Therapies in Multiple Myeloma: 22 (Resistance to Targeted Anti-Cancer Therapeutics, 22)

Genetic and Molecular Epidemiology of Multiple Myeloma

Myeloma Bone Disease (Current Clinical Oncology)